Stem cells from umbilical cord blood
The US Food and Drug Administration (FDA) has only approved one single cell therapy with stem cells to date. This is Hemacor, a product generated using stem cells from umbilical cord blood. It is prepared in the New York Blood Center, which launched its product on the market in 2011. It seems though that there are currently quite a few more cell therapies that are awaiting approval for commercial use (Nature Medicine 20; 797-798, 2014).
La entrada Cord blood – A new product using its stem cells has been developed aparece primero en Observatorio de Bioética, UCV.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.